Ubiquitination of epidermal growth factor receptor (EGFR) is required for downregulation of the receptor by endocytosis. Impairment of this pathway results in constitutively active EGFR, which is associated with carcinogenesis, particularly in lung cancer. We previously demonstrated that the deubiquitinating enzyme ubiquitin-specific protease 2a (USP2a) has oncogenic properties. Here, we show a new role for USP2a as a regulator of EGFR endocytosis. USP2a localizes to early endosomes and associates with EGFR, stabilizing the receptor, which retains active downstream signaling. HeLa cells transiently expressing catalytically active, but not mutant (MUT), USP2a show increased plasma membrane-localized EGFR, as well as decreased internalized and ubiquitinated EGFR. Conversely, USP2a silencing reverses this phenotype. Importantly, USP2a prevents the degradation of MUT in addition to wild-type EGFR. Finally, we observed that USP2a and EGFR proteins are coordinately overexpressed in non-small cell lung cancers. Taken together, our data indicate that USP2a antagonizes EGFR endocytosis and thus amplifies signaling activity from the receptor. Our findings suggest that regulation of deubiquitination could be exploited therapeutically in cancers overexpressing EGFR.
INTRODUCTION
The function of many plasma membrane receptors is regulated by endocytosis. Activated receptor tyrosine kinases (RTKs) generally internalize from the plasma membrane through clathrin-coated pits and vesicles, and are then delivered to early endosomes through flat clathrin microdomains. 1 Receptors can be recycled from early endosomes back to the plasma membrane or conveyed to lysosomes for degradation, a process that is dependent on ubiquitination. 2, 3 Conjugation of the small protein ubiquitin to these membrane proteins is the major component of the regulatory mechanism for their internalization and intracellular sorting. Ubiquitin conjugated to activated RTKs serves as a relay signal, directing their trafficking through the endosomal sorting machinery ESCRT (endosomal sorting complexes required for transport). 4 Aberrations in this negative regulation of RTKs can result in constitutively active RTK-dependent signaling and is associated with pathogenesis of cancer. 5, 6 Ubiquitination is a reversible post-translational modification. Conjugation of ubiquitin to substrate proteins and ubiquitin chains requires sequential cooperation of three enzymes, among which the ubiquitin protein ligase (E3) recognizes substrates and determines the specificity of ubiquitination. 7 Deubiquitinating enzymes (DUBs) deconjugate ubiquitin from substrates and from ubiquitin chains, thus negatively regulating ubiquitination. 8, 9 Much effort has been made to explore the roles of ubiquitin protein ligases (E3s) in mediating ubiquitination of RTKs, 10, 11 while little is known about the roles of DUB activity in this pathway.
Recently, two mammalian DUBs, AMSH and UBPY, have been implicated in the endocytic downregulation of the RTK epidermal growth factor receptor (EGFR). [12] [13] [14] Although both AMSH 15, 16 and UBPY 17, 18 show DUB activity on ubiquitinated EGFR, the effects of these DUBs on EGFR downregulation have been controversial. In some studies, both AMSH 15, 16 and UBPY 17, 19 were shown to prevent EGFR downregulation, apparently by deubiquitinating EGFR. In other studies, both AMSH 20, 21 and UBPY 15, 18, 22 have been reported to increase EGFR downregulation. Subsequently, the exact roles and mechanisms of DUBs in EGFR downregulation remain to be determined.
Our group has been investigating the DUB, ubiquitin-specific protease 2a (USP2a), as we have demonstrated that fatty acid synthase is a substrate of USP2a. 23 Other identified substrates of USP2a include cyclin D, 24 Mdm2, 25 MdmX 26 and Myc via microRNA-34b/c regulation. 27 Previously, we determined that purified recombinant UBP69, the mouse homolog of USP2a, interacts with clathrin heavy chain (CHC) in LNCaP cell lysates in an affinity chromatography experiment. 23 Clathrin is a structural protein required for internalization of RTKs and for their transport on early endosomes. 1, 4 Interaction between UBP69 and CHC suggests that USP2a could be involved in endocytosis. In addition, USP2a has been shown to localize to punctate structures in the cytoplasm, 28, 29 suggesting the protein may locate to early endosomes. We previously performed gene set enrichment analysis (GSEA) 30 on microarray expression data from human prostate cancers to determine whether overexpression of USP2a in tumors is associated with specific gene expression profiles. This analysis revealed that genes implicated in ErbB3, EEA1 and Rab pathways are upregulated in tumors overexpressing USP2a. 31 These three sets of genes are intimately involved with the endocytic pathway. Taken together, these data suggest a role for USP2a in the endosomal regulation of RTKs. As GSEA implicated the silent kinase ErbB3, which partners with EGFR, and because the most comprehensive studies of RTK endocytosis have been carried out using EGFR as an experimental model, we investigated the role of USP2a in EGFR endocytosis. We show here that USP2a stabilizes EGFR by preventing the degradation of the receptor by endocytosis.
RESULTS

USP2a localizes to early endosomes
As previous data suggested a role for USP2a in endocytosis, we first determined the subcellular localization of USP2a in HeLa cells. Exogenous GFP-USP2a (Figure 1a) showed a punctate pattern as assessed by immunofluorescence cell staining, and colocalized with the early endosomal antigen (EEA1). To independently assess the localization of USP2a at early endosomes, we enriched for endosomes from HeLa cell lysate by sucrose gradient centrifugation (Figure 1c) . Three different early endosome markers (EEA1, TfR (transferrin receptor) and Rab5) and a late endosome marker (Rab7) eluted in the expected fractions. 32 Endogenous USP2a peaks in the same fractions (no. 13 and 14) as EEA1, TfR and Rab5, but not as Rab7, which is instead enriched in late endosome fractions (no. 7-9). Furthermore, we confirm our prior finding 23 that USP2a is able to bind with another component of the endocytic pathway, CHC (Supplementary Figure S1) . Lack of colocalization of GFP-USP2a and late endosomal-lysosomal marker LAMP-1 by immunofluorescence is also shown in Supplementary Figure S2 . These data suggest that USP2a localizes to early but not to late endosomes or lysosomes.
USP2a stabilizes EGFR and decreases ubiquitinated forms of the receptor after EGF stimulation EGFR is known to be regulated by the endocytic pathway and has been shown to be regulated in part by deubiquitination. 33, 34 As a first step, we therefore assessed and demonstrated that USP2a and EGFR physically interact (Supplementary Figure S3) . Interestingly, 5 min of EGF treatment enhanced the coimmunoprecipitation of both transiently expressed and endogenous USP2a (Supplementary Figure S3) with EGFR, indicating that EGFR activation enhances an interaction between the two proteins.
We next investigated the role of USP2a in EGFR degradation (Figures 2a-c) . We generated a construct expressing a catalytically dead mutant of USP2a (MUT), which has the catalytic Cys (required for DUB activity) mutated to Ala, to assess whether the DUB activity is required for its role in EGFR regulation. After 3 h of EGF treatment, EGFR levels were significantly higher in the presence of transiently expressed wild-type USP2a (WT), but not the MUT of USP2a, than in the control cells (transfected with an empty vector), suggesting that the DUB activity of USP2a is required for this to occur (Figure 2a, upper panel) . In order to distinguish between an increase in EGFR translation versus enhanced degradation of the RTK secondary to WT USP2a activity, cycloheximide was used to inhibit protein biosynthesis. With cycloheximide treatment, EGFR levels remained high in the presence of WT USP2a after EGF stimulation (Figure 2a , lower panel and graph), indicating that USP2a stabilizes the EGFR protein. Furthermore, after quantitative analysis (Figure 2a , graphs), we confirmed our previous results 23, 31 that the catalytically dead USP2a MUT (C276A) acts as a dominant negative, that is, the degradation of EGFR is increased beyond the levels seen in the empty vector.
Importantly, the active form of EGFR, phospho-EGFR, was also stabilized in the presence of WT USP2a (Figure 2b ). The active form of Stat3 (Phospho-Stat3), an important downstream signaling molecule of EGFR pathway, 35 was elevated when WT USP2a was present, but total Stat3 was not (Figure 2b ), suggesting that signaling downstream of EGFR is promoted by WT USP2a. To address the specificity of the role of USP2a on EGFR, we observed (Supplementary Figure S4) that the overexpression of USP2a does not affect another membrane receptor, c-Met, whose degradation is also controlled by ubiquitination. 36, 37 These data support the assertion that the role of USP2a on EGFR is specific.
To determine whether endogenous USP2a stabilizes EGFR, we used USP2a siRNA to decrease USP2a in HeLa cells (Figure 2c , left panel). USP2a siRNA treatment, but not the non-targeting control siRNA, results in diminished retention of EGFR, confirming that USP2a protects EGFR from degradation ( Figure 2c, right panel) . These results were also confirmed by another USP2a siRNA (Supplementary Figure S5a) .
As ubiquitination has an important role in the degradation of EGFR [38] [39] [40] [41] [42] and USP2a stabilizes EGFR (Figures 2a-c) , we next investigated whether USP2a affects levels of ubiquitinated EGFR (Ub n -EGFR; Figure 2d ). Lysates of cells treated with EGF for 15 min (Figure 2d , right) or control (non-EGF treatment, Figure 2d , left) were immunoprecipitated with an anti-EGFR antibody. The precipitated samples were detected by western blot with an anti-ubiquitin antibody. Less Ub n -EGFR, detected by immunoblotting with the anti-ubiquitin antibody or with anti-phospho-EGFR antibody ( Figure 2d , lower panel), was observed after EGF treatment in the presence of WT USP2a than with MUT USP2a, suggesting that the DUB activity of USP2a is required for the decrease of Ub n -EGFR. Furthermore, USP2a siRNA treatment resulted in increased Ub n -EGFR (Supplementary Figure S6) , confirming that USP2a antagonizes EGFR ubiquitination.
Although monoubiquitination has been shown to be sufficient to direct lysosomal sorting of EGFR, 2,43,44 K63-linked polyubiquitin chains (K63-Ub n ), which are linked through lysine 63 within ubiquitin, might also promote the sorting of EGFR. 45 A mass spectrometry study 40 revealed that more than 50% of Ub n -EGFR is polyubiquitinated, predominantly through K63. Thus, K63-Ub n is likely to have an important role in this endocytic pathway. To determine if USP2a has DUB activity at K63-Ub n and another ubiquitin chain K48-Ub n , which is targets proteins for proteasomal degradation, 43 we performed an in vitro DUB assay ( Figure 2e ) with purified WT and MUT USP2a transiently expressed in HeLa cells. The amount of Ub chains were reduced and ubiquitin monomer appeared in the presence of WT USP2a (Figure 2e ), indicating that USP2a deubiquitinates both K48-Ub n and K63-Ub n in vitro.
USP2a enhances recycling of EGFR after EGF stimulation
To investigate how USP2a has a role in the EGFR endocytic pathway, we explored how depletion and overexpression of USP2a affect the amount of internalized EGFR after EGF stimulation. Cells were coupled with rhodamine-EGF at 4 1C and then chased at 37 1C for 15 min. Any labeled EGF left on the plasma membrane was removed by an acid wash. Cells were then fixed for microscopic detection. 21 AMSH, another DUB implicated in EGFR degradation in the multivesicular bodies pathway, showed no effect on EGFR internalization (Figure 3a , bottom horizontal row), indicating the specificity of USP2a in decreasing internalized EGFR. Accumulation of internalized Rhod-EGF was followed at different USP2a Figure S8a) . Conversely, knocking down USP2a by siRNA increased the amount of internalized EGF (Figure 3c; Supplementary Figure 9) . These results confirm that USP2a decreases internalized EGFR and that DUB activity is required for this decrease to occur. 
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We next explored whether USP2a levels affect the amount of plasma membrane-localized EGFR. At different time points of EGF treatment, live HeLa cells were coupled with an antibody against the N-terminus of EGFR, and then incubated with phycoerythrin, a red fluorescent-labeled secondary antibody. The cells were then analyzed by flow cytometry. Cells overexpressing WT USP2a had high fluorescence readings, indicating more plasma membranelocalized EGFR in the presence of WT USP2a than in the presence of the MUT USP2a or an empty vector (Figure 3d ). These cells exhibited a similar amount of plasma membrane-localized EGFR after serum starvation overnight, before EGF treatment (Supplementary Figure S8b) . In addition, both AMSH-WT and AMSH-MUT showed no effect on EGFR accumulation on plasma membrane (Supplementary Figure S8b) . On the other hand, cells treated with USP2a siRNA displayed less plasma membrane EGFR than controls (Figure 3e ). Taken together, these data suggest that USP2a decreases internalized EGFR, increases plasma membranelocalized EGFR following EGF stimulation, and that the DUB enzymatic activity of USP2a is required for this to occur.
Interestingly, after 5 min of EGF treatment, an insufficient time for EGFR recycling to occur, 46, 47 USP2a siRNA treatment had little, if any, effects on internalized (Figure 3c ) and plasma membranelocalized EGFR (Figure 3e ). The increase in internalized and decrease in plasma membrane-localized EGFR was detected 15 min following EGF treatment and continued until 30 min. These results suggest that these changes are the result of an enhanced recycling of EGFR mediated by USP2a, and not secondary to a decrease in either EGF uptake or EGFR internalization. To further explore the role of USP2a in EGFR recyling, a colocalization assay of the receptor with recycling endosomal marker Rab11 was performed after 5 min of EGF treatment (Figure 3f ). More EGFR colocalizes with Rab11 in the presence of exogenous GFP-USP2a (Figure 3f , two USP2a transfected cell at left) than the control (Figure 3f , non-transfected cells at right), confirming that USP2a enhances the recycling of EGFR. In addition, these results suggest that USP2a-enhanced EGFR recyling is targeted back to the plasma membrane.
USP2a stabilizes WT and MUT EGFR in NSCLC cell lines and correlates with EGFR protein expression in human NSCLC
We next investigated whether the regulation of EGFR by USP2a is relevant in cancer. Overexpression of EGFR has an important role in the pathogenesis and progression of NSCLC. 48, 49 To determine whether USP2a stabilizes EGFR in NSCLC, we first tested the effect of USP2a on WT EGFR in H358 and H2009 NSCLC cell lines. USP2a siRNA treatment resulted in diminished quantities of EGFR protein remaining after 2 h of EGF treatment in both lung cancer cell lines (Figure 4a, upper panel) , as is the case in HeLa cells (Figures 2a-c) , whereas EGFR increased with transiently expressed USP2a (Figure 4b) . EGFR mutations have an important role in NSCLC. The EGFR deletion mutation in exon 19 (E746-A750Del) and missense mutation L858R account for 90% of all the EGFR tyrosine kinase domain mutations. 50 Interestingly, USP2a silencing also resulted in decreased amounts of EGFR in both the EGFR L858R MUT in the H1975 NSCLC cell line and the EGFR MUT (E746-A750Del) in PC9 and HCC827 NSCLC cell lines (USP2a siRNA Oligo no. 1, Figure 4a , lower panel; USP2a siRNA Oligo no. 2, Supplementary Figure S5b) . These results suggest that USP2a protects both MUT and WT EGFR from degradation.
We then attempted to determine if we could observe a correlation between EGFR and USP2a expression in human NSCLC frozen tissues. Expression levels of EGFR and USP2a proteins in 16 cases of human NSCLC were determined by western blot (Supplementary Figure S10) . We performed weighted linear regression using EGFR and USP2a expressions in these specimens (Figure 4c) . A USP2a tumor/normal ratio (T/N) for each sample was used to allow the cases with higher T/N (the darker squares in Figure 4c ) to dominate the linear model fitting. The slope of the best fit line (dotted line in Figure 4c ) is 0.8195 and the corresponding F-test P-value of association is 0.0371, indicating that expression of the two proteins positively correlate (Figure 4c ). The mRNA expressions of EGFR in the tissues were determined by qPCR (Supplementary Figure S11) . Cases 3 and 7 show a significant elevation of EGFR mRNA in tumor. In contrast, the protein expression levels of EGFR were at similar levels in tumor and normal tissues in both cases. Therefore, the difference in EGFR protein expression we observed is presumably not due to EGFR gene amplification or activation.
DISCUSSION
Downregulation of EGFR-dependent signaling is achieved by internalization of activated EGFR and its degradation in lysosomes.
1 Ubiquitination of EGFR triggers endosomal sorting. This process can also be countered by the action of DUBs. There are multiple ubiquitin protein ligases (E3s) that function in the endocytic pathway as regulators of membrane protein trafficking and degradation. 10 Similarly, there could be several DUBs involved in the regulation of this pathway as well. Two mammalian DUBs (AMSH and UBPY) have thus far been assessed in terms of their effect on EGFR ubiquitination and degradation, but results remain controversial. [15] [16] [17] [18] [19] [20] [21] [22] In the present study, we have shown that USP2a is localized to early endosomes, and that it decreases ubiquitinated EGFR, internalized EGFR and degradation of EGFR, while increasing plasma membrane-localized EGFR. These effects did not appear early (at the 5 min time point) after EGF treatment, suggesting that USP2a has no effect on EGF uptake or clathrin-coated vesicles pinching off from the plasma membrane. Instead USP2a likely promotes recycling of the receptor to the USP2a prevents EGFR degradation Z Liu et al plasma membrane. Indeed, we observed more colocalization of EGFR with the recycling endosomal marker Rab11 in the presence of USP2a than the control. Taken together, our data support a model in which (1) USP2a triggers deubiquitination of EGFR on early endosomes; (2) deubiquitinated EGFR is recycled back to the plasma membrane rather than transported to lysosomes; and (3) USP2a thereby impedes sorting of EGFR to lysosomes for degradation ( Figure 5) .
The complex control of the internalization, sorting and turnover of EGFR suggests a prominent and essential role of deubiquitinating enzymes in this process. 12 We have determined that USP2a shows a specific role on internalized and plasma membranelocalized EGFR. Precisely where USP2a functions in the ESCRT machinery, however, remains to be determined. It is possible that USP2a works directly on EGFR and/or on the components of ESCRTs, for example, on STAM2 and Eps15 as in the cases for other DUBs. 16, 18, 51 In addition, there are other components of ESCRTs that are ubiquitinated, such as Hrs (hepatocyte growth factorregulated substrate) 52, 53 and Tsg 101 (tumor susceptibility gene 101). 54 Whether USP2a interacts with those components of ESCRTs, and whether some of them are substrates of USP2a remains to be determined. However, as we observed that USP2a binds to CHC (Supplementary Figure 1; Graner et al.
23
) and Hrs (an ESCRT-0 component 55 ) also interacts with clathrin and recruits other DUBs through STAM2 complex, we could speculate that USP2a acts in the early steps of ESCRTs recruitment/docking (ESCRT-0/I) rather than late steps of docking/assembly (ESCRT-II/III).
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USP2a shows oncogenic properties, and is overexpressed in prostate cancers 31 and NSCLC. We show here that transient expression of USP2a prevents the downregulation of EGFR, while USP2a RNA interference enhances the degradation of EGFR. Importantly, an increase in activated EGFR (phospho-EGFR) and enhanced/maintained EGFR downstream signaling occur in the presence of USP2a. Thus, stabilization of EGFR, MUT EGFR and activated (phosphorylated) EGFR by USP2a is likely to be an important mechanism underlying the oncogenicity of the protein, particularly in tumors driven by EGFR. Consistent with this conclusion, we observed a correlation between USP2a and EGFR expression in human NSCLC (Figure 4c ).
This study establishes USP2a as a positive regulator of EGFR by preventing its downregulation through the endocytic pathway. Our findings provide a better understanding of the oncogenic mechanism of USP2a, and may lead to new therapeutic strategies in EGFR-dependent cancers.
MATERIALS AND METHODS
Plasmid constructs and cell transfection wild type USP2a (WT) and the catalytic-dead MUT (C276A) 23 were subcloned into pEGFP, p-BABE and pDEST vectors. WT AMSH (WT-AMSH) and the catalytic-dead MUT AMSH (MUT-AMSH) 21 were gifts from Tomas Kirchhausen. HeLa and NSCLC cells were cultured in DMEM and RPMI (Gibco, Grand Island, NY, USA), respectively, supplemented with 10% fetal bovine serum and penicillin-streptomycin.
Fugene (Roche, Indianapolis, IN, USA) and Lipofectamine2000 (Invitrogen, Grand Island, NY, USA) were used for cell transfection. Cells were typically employed 24 h after transfection with suitable plasmids. USP2a siRNA (oligo no. 2, 80 nM), r(UGCUUGUGCCCGGUUCGAC)d(TT)] was used to deplete USP2a for 72 h. 23 A pool of four different oligos no. 1 (40 nM, Ontarget plus smart pool, Dharmacon, Lafayette, CO, USA, cat no. D-006069-00: 5 0 -CCAGCAAGCUCACAACAUUUU-3 0 ; 5 0 -UCGCUGACGUGUACAGAU UUU-3 0 ; 5 0 -GAACCUCGAUCAUCUUCCUUU-3 0 ; and 5 0 -GCCGACAGAUGUGGA GAAAUU-3 0 ) was also employed to knockdown human USP2a. 57, 58 Antibodies for western blot
Western blot was done as before. 31 The antibodies used were antibodies to HA (Covange, Berkeley, CA, USA), EGFR (Santa Cruz, Santa Cruz, CA, USA; 
Coimmunoprecipitation
Cells were lysed with TGH buffer (50 mM HEPES pH 7.3, 10% glycerol, 1% Triton X-100, 0.5 mM Na 3 VO 4 , 10 mM NEM, protease inhibitor tablet (Roche)). Cell lysate was incubated with protein A/G-Sepharose beads preloaded with anti-EGFR antibodies. Immunoprecipitates were washed by TGH buffer with and without 500 mM NaCl, three times each.
Immunofluorescence cell staining
HeLa cells were fixed with 4% paraformaldehyde, and then incubated in 1% BSA/10% normal goat serum/0.3 M glycine in 0.05% PBS-Tween for 1 h to permeabilize the cells and block non-specific protein-protein interactions. Cells were then incubated with anti-EEA1 antibody (Abcam) followed by Texas Red-secondary antibody. Nuclei were detected by Hoechst. Slides were mounted in Vectashield medium (Vector Laboratories, Inc., Burlingame, CA, USA) and analyzed using a Spinning Disk confocal microscope (Yokogawa, Oberkochen, Germany) for confocal studies or using an Axioplan 2 microscope (Carl Zeiss MicroImaging, Inc., Oberkochen, Germany) for EGFR internalization studies. The fluorescence signal within each cell was quantified using Image J (NIH image, Bethesda, MD, USA). A total of 40-50 cells were analyzed for each experimental condition.
Endosome isolation
The whole procedure was performed at 4 1C. 32 Cells were collected in PBS using a rubber scraper, centrifuged at 200 g for 5 min and subjected to hypotonic shock in homogenization buffer A (HBA; 3 mM imidazole, pH 7.4, 0.03 mM cycloheximide, 1 mM EDTA, protease and phosphatase inhibitors) for 20 min. An equal volume of HBB (500 mM sucrose in HBA) to that of HBA was added and cells were gently lysed by pipetting (P1000 blue tip). The homogenized cells were centrifuged at 2000 g for 10 min to retrieve the post-nuclear supernatant (PNS) and the nuclear pellet. The sucrose concentration of the PNS was adjusted to 40.6% by adding 62% sucrose. Diluted PNS was loaded on the bottom of the tube and sequentially overlaid with seven different sucrose (%) step gradient (35, 30, 27.5, 25, 20, 12.5, 8.6 ). The gradient was centrifuged at 210 000 g at 4 1C for 1.5 h (SW 41Ti rotor, Beckman, Brea, CA, USA). Fractions were collected from the top, labeled sequentially and protein content from each fraction precipitated by chloroform-methanol method 59 and solubilized in Laemmli-sample buffer.
Deubiquitination assay
Flag-USP2a was overexpressed in HeLa cells, purified by anti-Flag antibody-conjugated agarose beads (Sigma) and eluted with 3 Â Flag protein. In a 20-ml reaction, purified USP2a (0.4 mM) was incubated with K48-Ub n or K63-Ub n (Calbiochem; 0.3 mg), in the presence of DUB buffer (50 mM Tris-HCl, pH 7.2, 25 mM KCl, 5 mM MgCl 2 , 1mM DTT) at 37 1C for 18 h. 17 
EGFR degradation
Cells were serum-starved for 12 h, and stimulated with 100 ng/ml EGF for indicated time, with or without cycloheximide (10 mg/ml). Cells were lysed in lysis buffer (50 mM Tris-HCl, 0.5% NP-40, 100 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.5 mM Na 3 VO 4 , protease inhibitor tablet) and 20 mg of lysate from each experimental condition resolved by 4-12% gradient SDS-PAGE (Invitrogen). For quantification, the density of EGFR bands from replicates were measured with Quantity One 4.6.9 (BioRad, Hercules, CA, USA) and normalized to that of b-actin. 
Internalized EGFR
Statistical analysis
We performed weighted linear regression with the expressions of EGFR and USP2a in tumors using the lm routine in the R package. The USP2a expression T/N ratios for each sample were used to determine the weights, so that the line of regression is fitted closer to cases with higher values of the ratio.
Real-time reverse transcription-PCR
RNA from human lung tissues was reverse-transcribed with SuperScript III reverse transcription kit (Invitrogen). qPCR was done with the ABI Prism 7300 PCR instrument (Applied Biosystems, Foster City, CA, USA) by using TaqMAN Universal PCR Master Mix (Applied Biosystems). The primers for USP2a, EGFR, GUS were also from Applied Biosystems. The relative abundance of USP2a and EGFR transcripts were normalized to GUS levels using the 2 DDCt method.
